

Naturally Splendid Enterprises Ltd.

10:04 16 Oct 2020

Naturally Splendid answers Health Canada questions in progress toward Phase 2 coronavirus trial of cavaltinib

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) (FRA:50N), which is developing a coronavirus (COVID-19) treatment through a joint venture with Biologic Pharmamedical Research, responded to an information request notice from Health Canada, the company announced Friday.

The joint venture, Plasm Pharmaceutical, is preparing for a phase 2 coronavirus trial of its drug cavaltinib, and the questions from Health Canada are considered a formality, the company said.

"This COVID crisis is not going to end anytime soon," Biologic founder and Plasm Pharmaceutical lead researcher Franco Cavaleri said in a statement. "Although a vaccine will be the ultimate solution to the pandemic, we need alternative more immediate treatment strategies to reduce the degree of morbidity and risk of mortality for those who are vulnerable today. In this regard, we have been in dialogue with Health Canada to develop a final functional mutually acceptable phase 2 clinical trial for a COVID treatment, utilizing our Cavaltinib technology as the test drug."

READ: Naturally Splendid debuts new website as it prepares to roll out a slew of new plant-based products in North America

The lingering questions for Plasm concern the dosage of cavaltinib to be administered during the trial.

"On October 2, 2020, we responded to the latest information request notice (IRN) from Health Canada," Cavaleri said. "The IRN was designed to determine the final dosage of cavaltinib intended for use as a COVID treatment and to define the final criteria for the selection of patients making up the test and control groups for the trial. We have complied [with] the last requests made by Health Canada with regards to the experimental protocol and look forward to a final reply from Health Canada on these matters."

The company previously announced that it secured the necessary lab space and supply of cavaltinib to conduct the trial, in addition to significant manufacturing capacity in Canada and the US, should things go to plan.

Health Canada previously issued what is called a 'no objection' letter for cavaltinib, in response to Biologic's clinical trial application for the drug.


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.045

Market Cap: \$9.08 m

1 Year Share Price Graph



Share Information

Code: NSP

Listing: TSX-V

52 week High Low
0.14 0.025

Sector: Food & drink

Website: www.naturallysplendid.com

Company Synopsis:

NSE owns and operates a Safe Quality Food Level 2 food manufacturing facility and has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII™, Elevate Me™ and Woods Wild Bar. The Company has a myriad of new products and line extensions under development that are approaching launch.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).